RELMADA THERAPEUTICS, INC. Payments to Acquire Investments
RELMADA THERAPEUTICS, INC. (RLMD) reported Payments to Acquire Investments of $57.15 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2023-11-08
- RELMADA THERAPEUTICS, INC. payments to acquire investments for the quarter ending 2023-09-30 was $11.57M, a 107.39% increase year-over-year.
- RELMADA THERAPEUTICS, INC. payments to acquire investments for the quarter ending 2023-06-30 was $10.81M, a 44.21% increase year-over-year.
- RELMADA THERAPEUTICS, INC. payments to acquire investments for the quarter ending 2023-03-31 was $34.77M, a 34.15% increase year-over-year.
- RELMADA THERAPEUTICS, INC. payments to acquire investments for the quarter ending 2022-12-31 was $8.30M, a 94.09% decline year-over-year.
- RELMADA THERAPEUTICS, INC. payments to acquire investments for fiscal 2022 was $47.29M, a 78.79% decline from fiscal 2021.
- RELMADA THERAPEUTICS, INC. payments to acquire investments for fiscal 2021 was $222.98M, a 22.48% increase from fiscal 2020.
- RELMADA THERAPEUTICS, INC. payments to acquire investments for fiscal 2020 was $182.05M.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2023-09-30 | $11.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $22.38M derived: sum of 2 quarters · filed 2023-11-08 | $57.15M 10-Q · filed 2023-11-08 | $65.45M derived: sum of 4 quarters · filed 2023-11-08 |
| 2023-06-30 | $10.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $45.58M 10-Q · filed 2023-08-08 | $53.88M derived: sum of 3 quarters · filed 2023-08-08 | $59.46M derived: sum of 4 quarters · filed 2023-11-08 |
| 2023-03-31 | $34.77M 10-Q · filed 2023-05-11 | $43.07M derived: sum of 2 quarters · filed 2023-05-11 | $48.65M derived: sum of 3 quarters · filed 2023-11-08 | $56.15M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-12-31 | $8.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $13.88M derived: sum of 2 quarters · filed 2023-11-08 | $21.38M derived: sum of 3 quarters · filed 2023-11-08 | $47.29M 10-K · filed 2023-03-23 |
| 2022-09-30 | $5.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $13.08M derived: sum of 2 quarters · filed 2023-11-08 | $38.99M 10-Q · filed 2023-11-08 | $179.50M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $7.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $33.41M 10-Q · filed 2023-08-08 | $173.92M derived: sum of 3 quarters · filed 2023-08-08 | $199.52M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $25.92M 10-Q · filed 2023-05-11 | $166.42M derived: sum of 2 quarters · filed 2023-05-11 | $192.03M derived: sum of 3 quarters · filed 2023-05-11 | $228.23M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $140.51M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $166.11M derived: sum of 2 quarters · filed 2023-03-23 | $202.32M derived: sum of 3 quarters · filed 2023-03-23 | $222.98M 10-K · filed 2023-03-23 |
| 2021-09-30 | $25.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $61.81M derived: sum of 2 quarters · filed 2022-11-10 | $82.48M 10-Q · filed 2022-11-10 | $175.76M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $36.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $56.87M 10-Q · filed 2022-08-11 | $150.16M derived: sum of 3 quarters · filed 2022-08-11 | $176.56M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $20.66M 10-Q · filed 2022-05-05 | $113.95M derived: sum of 2 quarters · filed 2022-05-05 | $140.35M derived: sum of 3 quarters · filed 2022-05-05 | $165.48M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $93.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $119.69M derived: sum of 2 quarters · filed 2022-03-25 | $144.82M derived: sum of 3 quarters · filed 2022-03-25 | $182.05M 10-K · filed 2022-03-25 |
| 2020-09-30 | $26.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $51.53M derived: sum of 2 quarters · filed 2021-11-12 | $88.76M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $25.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $62.36M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $37.23M 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $84.85M 10-KT · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |